Anthera Pharmaceuticals, Inc. (ANTH) Reaches $0.30 Yearly Low; Bank Of America (BAC) Has 1.19 Sentiment

May 16, 2018 - By Vivian Currie

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) Logo

The stock of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) hit a new 52-week low and has $0.27 target or 9.00% below today’s $0.30 share price. The 5 months bearish chart indicates high risk for the $7.07M company. The 1-year low was reported on May, 16 by Barchart.com. If the $0.27 price target is reached, the company will be worth $636,120 less. The stock decreased 2.99% or $0.0093 during the last trading session, reaching $0.3021. About 222,729 shares traded. Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) has declined 90.50% since May 16, 2017 and is downtrending. It has underperformed by 102.05% the S&P500.

Bank Of America Corp (BAC) investors sentiment increased to 1.19 in 2017 Q4. It’s up 0.15, from 1.04 in 2017Q3. The ratio improved, as 747 hedge funds increased or started new holdings, while 627 sold and reduced positions in Bank Of America Corp. The hedge funds in our database now possess: 6.85 billion shares, down from 6.91 billion shares in 2017Q3. Also, the number of hedge funds holding Bank Of America Corp in top ten holdings increased from 202 to 233 for an increase of 31. Sold All: 66 Reduced: 561 Increased: 585 New Position: 162.

Bank of America Corporation, through its subsidiaries, provides banking and financial services and products for individual consumers, small and middle-market businesses, institutional investors, large firms, and governments worldwide. The company has market cap of $315.57 billion. It operates through four divisions: Consumer Banking, Global Wealth & Investment Management, Global Banking, and Global Markets. It has a 19.96 P/E ratio. The Consumer Banking segment offers traditional and money market savings accounts, CDs and IRAs, noninterest- and interest-bearing checking accounts, and investment accounts and products, as well as credit and debit cards, residential mortgages and home equity loans, and direct and indirect loans.

The stock decreased 0.31% or $0.097 during the last trading session, reaching $31.123. About 20.61M shares traded. Bank of America Corporation (BAC) has risen 28.18% since May 16, 2017 and is uptrending. It has outperformed by 16.63% the S&P500.

Daily Journal Corp holds 39.31% of its portfolio in Bank of America Corporation for 2.30 million shares. Toscafund Asset Management Llp owns 1.35 million shares or 20.86% of their US portfolio. Moreover, Theleme Partners Llp has 18.43% invested in the company for 13.32 million shares. The New York-based Salzhauer Michael has invested 17.67% in the stock. First Trust Bank Ltd., a Bahamas-based fund reported 210,721 shares.

More notable recent Bank of America Corporation (NYSE:BAC) news were published by: Seekingalpha.com which released: “Bank Of America: Time To Sell?” on May 08, 2018, also Seekingalpha.com with their article: “Bank of America affirms gun pledge” published on May 11, 2018, Seekingalpha.com published: “Bank Of America: Into The Home Straight?” on April 23, 2018. More interesting news about Bank of America Corporation (NYSE:BAC) were released by: Seekingalpha.com and their article: “Bank of America (BAC) Investor Presentation – Slideshow” published on April 26, 2018 as well as Nasdaq.com‘s news article titled: “A Vicious Debt Cycle Could Send Interest Rates Much Higher” with publication date: May 16, 2018.

Ratings analysis reveals 25% of Bank of America’s analysts are positive. Out of 8 Wall Street analysts rating Bank of America, 2 give it “Buy”, 0 “Sell” rating, while 6 recommend “Hold”. The lowest target is $17.0 while the high is $26.0. The stock’s average target of $21.46 is -31.05% below today’s ($31.123) share price. BAC was included in 9 notes of analysts from September 13, 2016. The firm has “Hold” rating given on Tuesday, September 13 by Societe Generale. The firm earned “Neutral” rating on Tuesday, November 15 by Guggenheim. The stock of Bank of America Corporation (NYSE:BAC) earned “Hold” rating by Standpoint Research on Thursday, December 1. The firm has “Buy” rating by Citigroup given on Wednesday, January 11. As per Tuesday, November 8, the company rating was downgraded by Deutsche Bank. Macquarie Research upgraded the stock to “Outperform” rating in Thursday, February 16 report. The rating was maintained by Barclays Capital on Tuesday, January 3 with “Equal Weight”. The firm has “Neutral” rating by Robert W. Baird given on Wednesday, November 16.

Analysts await Bank of America Corporation (NYSE:BAC) to report earnings on July, 17. They expect $0.64 earnings per share, up 39.13% or $0.18 from last year’s $0.46 per share. BAC’s profit will be $6.49 billion for 12.16 P/E if the $0.64 EPS becomes a reality. After $0.62 actual earnings per share reported by Bank of America Corporation for the previous quarter, Wall Street now forecasts 3.23% EPS growth.

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. The company has market cap of $7.07 million. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy. It currently has negative earnings.

Bank of America Corporation (NYSE:BAC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: